reports
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring ...
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congre...
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025...
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101 Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), een wereldwijd biotechnologiebedrijf dat zich toelegt op het veranderen van de resultaten voor patiënten door middel van levensveranderende wetenschap en innovatie, kondigde vandaag aan dat nieuwe gegevens uit haar lopende ATALANTA-1 fase 1/2-studie met GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom (R/R NHL) geaccepteerd zijn voor ...
- Jacob Mekhael
Galapagos 1-1 mgmt. call feedback on re-evaluation of company split
We had a 1-1 call with Galapagos' mgmt. including Henry Gosebruch, newly appointed CEO, and Jérôme Contamine, newly appointed chairman of the board following this morning's announcement regarding the re-evaluation of the proposed company split in favour of strategic alternatives for the cell therapy business. Our takeaway is this new approach leads to a similar outcome intended with the split, but through a smoother path. We summarise our key takeaways in this note.
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Galapagos Re-evaluates split in favour of strategic options for cell t...
Galapagos announced that the previously announced company split has been re-evaluated, and instead the company will explore strategic options for the cell therapy business. Henry Gosebruch has been appointed as CEO of Galapagos, replacing Paul Stoffels, effective immediately, and will lead the strategic evaluation process, while also focusing on building a new pipeline through business development. While we find the timing a bit of a surprise, we do note that this outcome could increase the cash...
Galapagos Announces Strategic Update on Proposed Separation, Executive...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced hi...
Galapagos kondigt een strategische update aan over de geplande splitsi...
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur Galapagos heroverweegt uitvoering van eerder aangekondigde splitsing naar aanleiding van ontwikkelingen in regelgeving en de markt Galapagos onderzoekt alle strategische alternatieven voor haar bestaande activiteiten, waaronder celtherapie, met de nadruk op het maximaliseren van de beschikbare middelen voor transformatieve business development transacties De heer Henry Gosebruch is door de Raad van Bestuur van Galapagos benoemd t...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Stefano Toffano
- Thomas Zlowodzki
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DGE DIAGEO PLC
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
CEN GROUPE CRIT SA
IDL ID LOGISTICS GROUP
SDG SYNERGIE SA
SBS STRATEC SE
GYC GRAND CITY PROPERTIES SA
POM PLASTIC OMNIUM SE
SCR SCOR SE
SZG SALZGITTER AG
ITP INTERPARFUMS
AUB AUBAY SA
FNAC FNAC DARTY SA
VNA VONOVIA SE
VOE VOESTALPINE AG
ACX ACERINOX SA
MBB MBB INDUSTRIES SE
BB SOCIETE BIC SA
ERA ERAMET SA
ROS ROSENBAUER INTERNATIONAL AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
NDA AURUBIS AG
TPS ORANGE POLSKA S.A.
TEG TAG IMMOBILIEN AG
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
LEG LEG IMMOBILIEN AG
PYT POLYTEC HOLDING
CSM CORBION NV
WLN WORLDLINE SA
COFA COFACE SA
GLPG GALAPAGOS NV
RIO RIO TINTO PLC
XFAB X-FAB SILICON FOUNDRIES SE
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
VRLA VERALLIA SAS
CPR DAVIDE CAMPARI-MILANO N.V.
FUR FUGRO NV
AZE AZELIS GROUP NV
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
- Stefano Toffano
- Thomas Zlowodzki
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DGE DIAGEO PLC
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
CEN GROUPE CRIT SA
IDL ID LOGISTICS GROUP
SDG SYNERGIE SA
SBS STRATEC SE
GYC GRAND CITY PROPERTIES SA
POM PLASTIC OMNIUM SE
SCR SCOR SE
SZG SALZGITTER AG
ITP INTERPARFUMS
AUB AUBAY SA
FNAC FNAC DARTY SA
VNA VONOVIA SE
VOE VOESTALPINE AG
ACX ACERINOX SA
MBB MBB INDUSTRIES SE
BB SOCIETE BIC SA
ERA ERAMET SA
ROS ROSENBAUER INTERNATIONAL AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
NDA AURUBIS AG
TPS ORANGE POLSKA S.A.
TEG TAG IMMOBILIEN AG
SESL SES-IMAGOTAG SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
LEG LEG IMMOBILIEN AG
PYT POLYTEC HOLDING
CSM CORBION NV
WLN WORLDLINE SA
COFA COFACE SA
GLPG GALAPAGOS NV
RIO RIO TINTO PLC
XFAB X-FAB SILICON FOUNDRIES SE
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
VRLA VERALLIA SAS
CPR DAVIDE CAMPARI-MILANO N.V.
FUR FUGRO NV
AZE AZELIS GROUP NV
SPM SAIPEM S.P.A.
FLOW FLOW TRADERS LTD
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Galapagos 1Q25 update selects MCL as lead CAR-T indication, more data ...
Galapagos reported 1Q25 results with € 3.3b in cash and reiterated its cash burn guidance of € 175-225m (excl. restructuring costs). In the pipeline, the company provided more clarity on the path to market and selected MCL as lead indication, for which pivotal development is planned to begin in 2026. While Tecartus is already approved in that setting, it comes with burdensome toxicity and sales have plateaued. As such, we think GLPG5101's low rates of grade =3 CRS/ICANS could be a differentiator...
Galapagos Reports First Quarter 2025 Financial Results, Recent Busines...
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Foun...
Galapagos rapporteert resultaten over het eerste kwartaal van 2025, re...
Galapagos rapporteert resultaten over het eerste kwartaal van 2025, recente hoogtepunten en verwachtingen op korte termijn Eerste Amerikaanse patiënt gedoseerd in ATALANTA-1 studie met GLPG5101 Mantelcellymfoom (MCL), een hematologische maligniteit met een hoge onvervulde behoefte, geselecteerd als hoofdindicatie voor het GLPG5101-programma; pivotale ontwikkeling gepland voor start in 2026, met als doel goedkeuring in 2028 Wijzigingen in het uitvoerend leidershap met het pensioen van Dr. Paul Stoffels als CEO na de benoeming van zijn opvolger, terwijl hij aanblijft als Voorzitter van ...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Galapagos New SpinCo CEO appointed, Paul Stoffels to retire as Galapag...
Galapagos announced two executive leadership updates including i) the appointment of Henry Gosebruch as CEO of the SpinCo following the previously announced company split, while ii) Paul Stoffels has informed the board of his intent to retire from his role as CEO upon appointment of a successor, and to remain as non-executive chair of the Galapagos board. We are encouraged by the appointment of a well experienced executive to lead SpinCo, while Paul Stoffels' decision to retire as CEO comes as a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.